Key Takeaways:
-
Bloom’s lead candidate, BL-001, comprises two microbes that replicate the antiepileptic effects of the ketogenic diet.
-
The program has completed Phase I development with Phase II studies planned in seizures due to Dravet syndrome and ALS.
-
Bloom also has a preclinical program that addresses oxidative stress in ALS to slow disease progression.
The US firm was founded in 2018 by CEO Christopher Reyes, a biophysicist by training who started his entrepreneurial career heading up the Biogen, Inc. spinout Eclipse Therapeutics
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?